Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

Autor:	Catherine Chassagne-Clément, Marie Maerevoet, Clémentine Sarkozy, Dolores Caballero, Lars Moller Pedersen, Hervé Ghesquières, Sirpa Leppä, Gilles Salles, Richard Delarue, Christophe Fermé, John F. Seymour, Maria Gomes da Silva, Christiane Mounier
Rok vydání:	2014
Předmět:	medicine.medical_specialty Pathology Hematology biology business.industry Immunology Follicular lymphoma Cell Biology medicine.disease Biochemistry Lymphoma Leukemia hemic and lymphatic diseases Internal medicine Monoclonal medicine biology.protein Disseminated disease Rituximab Antibody business medicine.drug
Zdroj:	Blood. 123:2740-2742
ISSN:	1528-0020 0006-4971
DOI:	10.1182/blood-2014-02-553693
Popis:	To the editor: Follicular lymphoma is typically a disseminated disease with frequent bone marrow infiltration at the time of diagnosis,[1][1] but only a few patients manifest detectable circulating peripheral blood lymphoma cells (CLC).[2][2][⇓][3][⇓][4]-[5][5] We recently described the poor
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f90a39ed86546e5d7ca3e0d5ce7e433b https://doi.org/10.1182/blood-2014-02-553693 Zobrazit plný text záznamu